FULC
NASDAQ
$3.62
Fulcrum Therapeutics Inc (FULC)
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Sell
Target: $5.83 (+61.05%)
Market Cap
$237M
P/B Ratio
0.72
Profit Margin
69.3%
Free Cash Flow Yield
-26.94%
Price Chart
Valuation
Market Cap$237M
P/S2.66
P/B0.72
Profitability
Gross Profit (TTM)-$57M
EBITDA-$85M
Profit Margin69.3%
Operating Margin65.6%
EPS-$1.27
Financial Health
Free Cash Flow Yield-26.94%
Growth & Risk
EPS 5Y CAGR-12.14%
FCF 5Y CAGR+2.77%
Beta (5Y)1.19
Sharpe Ratio-0.28